Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...
Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback